Comparison
Noopept vs Cerebrolysin
Noopept
Russian-developed proline-containing dipeptide ~1000x more potent than piracetam by weight. Often grouped with racetams.
Cerebrolysin
Porcine brain-derived peptide mixture. Injectable. Used in Europe and Asia for stroke and dementia.
| Field | Noopept | Cerebrolysin |
|---|---|---|
| Category | peptide | peptide |
| Dose range | 10–30mg | 5–30mg |
| Half-life | 0.5h | — |
| Onset | 20min | — |
| Evidence | EVIDENCEB | EVIDENCEB |
| Safety | ●●●●○ | ●●●○○ |
| Legal (US) | USUnscheduled | USResearch chemical |
| PubMed refs | 90 | 380 |
The comparison in plain English
Auto-generated from dataNoopept and Cerebrolysin are both in the peptide category respectively. Noopept Russian-developed proline-containing dipeptide ~1000x more potent than piracetam by weight. Cerebrolysin Porcine brain-derived peptide mixture.
Bottom line
Noopept (evidence B, safety 4/5) matches the evidence base of Cerebrolysin (evidence B, safety 3/5). Noopept has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Noopept if
Noopept is the better fit when your goal aligns with its mechanism (Increases BDNF and NGF expression in the hippocampus and prefrontal cortex) and the dose range (10–30mg) suits your protocol. Half-life is 0.5h.
Choose Cerebrolysin if
Cerebrolysin is the better fit when your goal aligns with its mechanism (Heterogeneous mixture of low-molecular-weight peptides and amino acids derived from enzymatic hydrolysis of porcine brain tissue) and the dose range (5–30mg) suits your protocol. Half-life is —h.